Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide for the Reduction of Arrhythmia Burden in Overweight and Obese Patients With Atrial Fibrillation (Pilot Study)

NCT04885634 is registered in ClinicalTrials.gov with Axel Brandes as lead sponsor.

NCT NCT04885634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04885634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide for the Reduction of Arrhythmia Burden in Overweight and Obese Patients With Atrial Fibrillation (Pilot Study)
Lead sponsor
Axel Brandes
Phase
Phase 3
Overall status
Withdrawn
Start date
October 31, 2022
Completion date
November 30, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, overweight and obesity